Think | Create | Scale
Follow
  • Startup Pulse
    altM raises $10.3 million in a Series A round led by Rainmatter by Zerodha and Mela Ventures, with Omnivore, Theia Ventures, Aureolis Ventures, Spectrum Impact and strategic angel investors participating. Venomics AI raises $2.7 million in a pre-seed round co-led by Speciale Invest and South Park Commons, with Operators Studio participating. EloElo Group raises $80 million in a Series C round led by Hornbill Capital and NBCUniversal, with MIT Investment Co. and existing investors participating. Peppermint Robotics raises ₹100 crore (approximately $10.5 million) in a Pre-Series B round led by pi Ventures and Crane Venture Partners, with Asiana Fund participating. Traversal raises $120 million in a Series B round at a $1 billion valuation, led by Kleiner Perkins, Redpoint and Khosla Ventures, with Sequoia Capital, Battery Ventures and Amex Ventures participating. GIVA raises over $100 million in a round led by Multiples Alternate Asset Management. The Croffle Guys raises ₹14 crore in a round led by V3 Ventures, with N.A.N Partners participating. Solgram raises over $1 million in a pre-seed round led by DSG Consumer Partners and Saama Capital, with Kapil Chopra participating. Sachin Tendulkar makes a strategic investment in Metasports Interactive, the company behind Hitwicket. The amount was not disclosed. Hyeglo Beauty raises ₹7 crore in a round led by Sauce, with Giga Capital, Consumer Collective, Reckitt's Arjun Purkayastha and The Patient Capital participating. altM raises $10.3 million in a Series A round led by Rainmatter by Zerodha and Mela Ventures, with Omnivore, Theia Ventures, Aureolis Ventures, Spectrum Impact and strategic angel investors participating. Venomics AI raises $2.7 million in a pre-seed round co-led by Speciale Invest and South Park Commons, with Operators Studio participating. EloElo Group raises $80 million in a Series C round led by Hornbill Capital and NBCUniversal, with MIT Investment Co. and existing investors participating. Peppermint Robotics raises ₹100 crore (approximately $10.5 million) in a Pre-Series B round led by pi Ventures and Crane Venture Partners, with Asiana Fund participating. Traversal raises $120 million in a Series B round at a $1 billion valuation, led by Kleiner Perkins, Redpoint and Khosla Ventures, with Sequoia Capital, Battery Ventures and Amex Ventures participating. GIVA raises over $100 million in a round led by Multiples Alternate Asset Management. The Croffle Guys raises ₹14 crore in a round led by V3 Ventures, with N.A.N Partners participating. Solgram raises over $1 million in a pre-seed round led by DSG Consumer Partners and Saama Capital, with Kapil Chopra participating. Sachin Tendulkar makes a strategic investment in Metasports Interactive, the company behind Hitwicket. The amount was not disclosed. Hyeglo Beauty raises ₹7 crore in a round led by Sauce, with Giga Capital, Consumer Collective, Reckitt's Arjun Purkayastha and The Patient Capital participating.

    • Just In

    Anti-Cancer Medicines to Get Cheaper From November 9: Is Your Cancer Drug on the List?

    Health Posted on  —by Salil Urunkar

    Share

    Anti-Cancer Medicines become affordable in India

    New Delhi: Anti-Cancer Medicines are set to become significantly more affordable in India, with revised prices of over 1,000 drug brands coming into effect from November 9, 2026.

    The government has reported substantial price reductions across cancer drug formulations, with some brands witnessing price cuts of more than 50% and the highest reduction reaching 96.45%.

    The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has capped trade margins on the maximum retail prices (MRP) of 137 anti-cancer drugs.

    The move is aimed at improving the affordability and accessibility of essential medicines used in cancer treatment.

    According to the government, the revised prices will result in estimated annual savings of ₹3,502.31 crore for consumers.

    Anti-Cancer Medicines: More Than 1,000 Formulations Witness Price Reductions

    As of November 7, 2026, a total of 76 pharmaceutical companies have reported revised MRPs for 1,225 formulations of anti-cancer medicines, covering 121 drugs.

    Of these, 1,031 formulations have reported reductions in their maximum retail prices. Furthermore, 600 brands have registered price reductions exceeding 50%, while the highest reported reduction stands at 96.45%.

    The government has also clarified that 10-15 drugs among the 137 identified anti-cancer drugs are yet to be launched in India. However, Trade Margin Rationalisation (TMR) will also apply to these medicines once they are introduced in the Indian market.

    Anti-Cancer Medicines: Major Brands See Significant Price Cuts

    The revised pricing has brought down the prices of several widely used anti-cancer drug formulations, including medicines prescribed for breast, prostate, lung, colon, ovarian, cervical and blood cancers.

    Some of the major price revisions announced by the government include:

    1. Bevacizumab 100 MG Injection

    Bevacizumab is used in the treatment of lung, colon, ovarian and cervical cancers. Several brands of this formulation have witnessed substantial price reductions.

    • Bryxta (Zydus Lifesciences): Reduced from ₹25,995 to ₹3,318.
    • BevaciRel (Reliance Life Sciences): Reduced from ₹24,079 to ₹3,985.
    • CIZUMAB (Hetero Healthcare): Reduced from ₹15,658 to ₹3,103.
    • Versavo (Dr. Reddy’s Laboratories): Reduced from ₹7,686 to ₹3,504.23.

    2. Denosumab 60 MG Injection

    Denosumab is used by breast and prostate cancer patients to prevent bone loss.

    • DenOsteoRel (Reliance Life Sciences): Reduced from ₹24,955 to ₹6,240.
    • Debrumab (RPG Life Sciences): Reduced from ₹22,031.25 to ₹5,941.
    • Denoclast (Zydus Lifesciences): Reduced from ₹19,687.50 to ₹7,334.84.
    • ROZEL (Intas Pharmaceuticals): Reduced from ₹15,458.40 to ₹6,825.50.

    3. Abiraterone Acetate 250 MG Tablet

    Abiraterone acetate is used in the treatment of prostate cancer.

    • ABIRONE (Arvincare Pharma): Reduced from ₹41,250 to ₹3,218.23.
    • ABIRAT (Khandelwal Laboratories): Reduced from ₹36,088.81 to ₹4,064.48.
    • AHABIR (Hetero Healthcare): Reduced from ₹33,876.50 to ₹4,925.
    • Abirapro (Glenmark Pharmaceuticals): Reduced from ₹28,744 to ₹5,768.

    4. Pegfilgrastim 6 MG Injection

    Pegfilgrastim is used to prevent neutropenia in cancer patients.

    • PEG FILTERO (Hetero Healthcare): Reduced from ₹9,093 to ₹1,631.
    • Peg-ReliGrast (Reliance Life Sciences): Reduced from ₹5,331 to ₹1,258.
    • Pegex (Gennova Biopharmaceuticals): Reduced from ₹6,270.45 to ₹1,527.78.
    • Peg Frastim (RPG Life Sciences): Reduced from ₹6,660.85 to ₹1,807.

    5. Azacitidine 100 MG Injection

    Azacitidine is used in the treatment of blood cancer.

    • AzatiRel (Reliance Life Sciences): Reduced from ₹7,790 to ₹1,397.
    • AZADINE (Intas Pharmaceuticals): Reduced from ₹5,964.70 to ₹1,199.50.
    • Azacytin (Dr. Reddy’s Laboratories): Reduced from ₹6,337 to ₹1,495.04.
    • Azadual 100 (MSN Laboratories): Reduced from ₹4,852.03 to ₹1,207.80.

    6. Enzalutamide 40 MG Capsule

    Enzalutamide is prescribed for prostate cancer treatment.

    • ENZAPTOR 40 (Halsted Pharma): Reduced from ₹20,625 to ₹2,475.60.
    • XTIDE (Eris Lifesciences): Reduced from ₹10,828.12 to ₹1,729.21.
    • Enzuta (Emcure Pharmaceuticals): Reduced from ₹20,667 to ₹4,157.65.
    • ENZAMIDE (Intas Pharmaceuticals): Reduced from ₹10,781.25 to ₹3,536.50.

    7. Fulvestrant 250 MG Injection

    Fulvestrant is used in the treatment of breast cancer.

    • FASNORM (Eris Lifesciences): Reduced from ₹30,421.87 to ₹3,671.73.
    • FULZOS (Hetero Healthcare): Reduced from ₹16,500 to ₹3,215.
    • Fulvira (Emcure Pharmaceuticals): Reduced from ₹16,694.95 to ₹3,900.41.
    • FISTENT INJ (Adley Formulations): Reduced from ₹22,600 to ₹6,031.50.

    8. Palbociclib 125 MG Capsule

    Palbociclib is another medicine used in breast cancer treatment.

    • Palbopro (RPG Life Sciences): Reduced from ₹40,421.33 to ₹2,720.
    • PALBOMED (Medicamen Biotech): Reduced from ₹13,500 to ₹2,302.
    • PICLIB (Hetero Healthcare): Reduced from ₹7,801.50 to ₹2,058.
    • Palborest 125 (MSN Laboratories): Reduced from ₹2,246 to ₹791.80.

    9. Pemetrexed 500 MG Vial

    Pemetrexed is used in the treatment of lung cancer.

    • ReliTrexed (Reliance Life Sciences): Reduced from ₹9,977 to ₹1,113.
    • PEMETOMED (Medicamen Biotech): Reduced from ₹5,062 to ₹940.
    • ADPEM 500 (Adley Formulations): Reduced from ₹5,499 to ₹1,035.05.
    • Pemgem (Dr. Reddy’s Laboratories): Reduced from ₹7,032 to ₹3,408.64.

    10. Pertuzumab 420 MG Injection

    Pertuzumab is used in breast cancer treatment.

    • LUPIHER 2 (Lupin): Reduced from ₹83,520 to ₹37,358.35.
    • Womab (Dr. Reddy’s Laboratories): Reduced from ₹74,992.50 to ₹53,708.19.
    Government Caps Trade Margins to Improve Cancer Treatment Affordability

    The government stated that Trade Margin Rationalisation of non-scheduled anti-cancer medicines is an important step towards improving the affordability and accessibility of essential medicines for cancer care.

    The notification SO 5690 (E), dated October 17, 2026, will remain in force until further orders.

    However, pharmaceutical manufacturers will be permitted to undertake annual price increases under Paragraph 20(1) of the Drugs (Prices Control) Order, 2013, subject to continued compliance with the maximum permissible trade margin of 30%.

    NPPA Directs Retailers, Hospitals to Display Revised Drug Prices

    Under the revised pricing framework, every retailer, dealer, hospital and medical institution will be required to prominently display the revised MRP lists of anti-cancer medicines on their websites and premises.

    The NPPA has also stated that State Drug Controllers will monitor compliance with the revised pricing requirements by manufacturers, dealers, hospitals and medical institutions.

    Consumers can verify the applicable prices of anti-cancer medicines through the Pharma Sahi Daam mobile application and the NPPA website.

    Consumers can also report instances of non-compliance or violations of the revised prices to the authority through the following channels:

    • Email: monitoring-nppa[at]gov[dot]in
    • Helpline: 1800-11-1255
    • Postal Address: Deputy Director, Monitoring, NPPA, 3rd Floor, YMCA Cultural Centre Building, 1 Jai Singh Marg, New Delhi – 110001.

    The revised pricing framework is expected to reduce the financial burden on cancer patients and their families, with the government estimating annual consumer savings of ₹3,502.31 crore.

    Author

    • Salil Urunkar

      Salil Urunkar is a senior journalist and the editorial mind behind Sahyadri Startups. With years of experience covering Pune’s entrepreneurial rise, he’s passionate about telling the real stories of founders, disruptors, and game-changers.

    Share

    Related Posts

    Sahyadri Startups
    Copyright © 2026. All rights reserved. Powered by Rumanvay Growth Partners LLP Powered by Probewise.
    Back to top